RecruitingPhase 2NCT06614894
An Open Label Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacologic Properties of High Dose Ambroxol Hydrochloride in Adult (≥ 18 Years of Age) Subjects With MPS III
Studying Sanfilippo Syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ozlem Goker-Alpan
- Principal Investigator
- Ozlem Goker-Alpan, MDLysosomal & Rare Disorders Research & Treatment Center, Inc.
- Intervention
- Ambroxol Hydrochloride 30 mg tablet - 9 mg/kg/day(drug)
- Enrollment
- 10 enrolled
- Eligibility
- 18-99 years · All sexes
- Timeline
- 2024 – 2026
Study locations (1)
- Lysosomal & Rare Disorders Research & Treatment Center, Inc., Fairfax, Virginia, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06614894 on ClinicalTrials.govOther trials for Sanfilippo Syndrome
Additional recruiting or active studies for the same condition.